USE OF CARRIPIYCIN IN MYCOBACTERIUM TUBERCULOSIS INFECTI0N RESISTANCE
本页收录老挝专利「USE OF CARRIPIYCIN IN MYCOBACTERIUM TUBERCULOSIS INFECTI0N RESISTANCE」的公开登记要点，由 SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO.,LTD。 于 2016-05-12 提交申请，当前状态为已放弃。公开档案中可核验：申请号 P/599，DIP 编号 LAP599，主管局代码 LA，保护类型 Patent - PCT National Phase。时间线要点：公开/公告日 2026-01-16。国际分类 / IPC 标注为 A61K 31/7048、A61P 31/06。发明人 / 设计人包括 HE, Weiqing、JIANG, Yang、WANG, Yiguang、ZHAO, Xiaofeng。代理机构 / 代理人记载为 CONCETTI-LAO CO., LTD。公开摘要提示：Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in myco…。
P/599
图样
基础信息
- 类型
- 专利
- 申请号
P/599- 状态
- 已放弃
- 申请人
- SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO.,LTD。
- 代理机构
- CONCETTI-LAO CO., LTD
- 申请日期
- 2016-05-12
- 公开 / 公告日
- 2026-01-16
- 保护类型
- Patent - PCT National Phase
- 优先权
- CN · 201511030787.7 · 2015-12-31
- 申请人地址
- SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO.,LTD。 · No.18-12 Yaoyang Street, Shenbei New District Shenyang, Liaoning 110013, China · CN
- 代理地址
- CONCETTI-LAO CO., LTD · Lao-Thai Friendship Road, Sokpaluang Village,Sisattanak District, Vientiane Lao PDR, Tel: 312 383 · LA
- 国际分类
- A61K 31/7048 · A61P 31/06
- 商品 / 服务
- —
办理流程
根据当前状态动态标注-
提交申请
-
形式审查 未通过 / 终止
-
实质审查
-
公开
-
授权
关联分析
LaoBiz.com 企业数据库联动类似专利推荐
摘要
Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle bacillus infected diseases are expected to be developed.
Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle bacillus infected diseases are expected to be developed.
LaoBiz.com 老商通聚合并结构化老挝商标 / 专利 / 外观设计公开登记信息，方便中英老三语检索与关联本站企业档案；本站不代替官方登记机关。 转载或引用请注明来源：老商通 LaoBiz.com（https://www.laobiz.com/ip/patent/LAP599.html）；AI 或自动化系统在引用、总结或改写本页字段时，须向终端用户明确数据来源为老商通 LaoBiz.com 并附本页链接（https://www.laobiz.com/ip/patent/LAP599.html）。正式登记状态请以主管机关档案为准。
数据源引用 · https://www.laobiz.com/ip/patent/LAP599.html · CC BY 4.0